ProKidney Corp.(PROK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PROK ProKidney Corp.

Not Yet Opened 12-22 16:00:00 EST

2.46

+0.09

+3.80%

盘后2.49

+0.03+1.22%

19:12 EST

High2.52	Low2.37	Vol613.19K
Open2.37	D1 Closing2.37	Amplitude6.12%
Mkt Cap740.05M	Tradable Cap674.43M	Total Shares300.83M
T/O1.51M	T/O Rate0.22%	Tradable Shares274.16M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PROK","market":"US","secType":"STK","nameCN":"ProKidney Corp.","latestPrice":2.46,"timestamp":1766437200000,"preClose":2.37,"halted":0,"volume":613193,"hourTrading":{"tag":"盘后","latestPrice":2.49,"preClose":2.46,"latestTime":"19:12 EST","volume":3144,"amount":7704.716,"timestamp":1766448725935},"delay":0,"floatShares":274159714,"shares":300834400,"eps":-0.543298,"marketStatus":"Not Yet Opened","change":0.09,"latestTime":"12-22 16:00:00 EST","open":2.37,"high":2.515,"low":2.37,"amount":1506556.7023878,"amplitude":0.061181,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.543298,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766480400000},"marketStatusCode":0,"adr":0,"listingDate":1625025600000,"exchange":"NASDAQ","adjPreClose":2.37,"preHourTrading":{"tag":"盘前","latestPrice":2.39,"preClose":2.37,"latestTime":"09:18 EST","volume":3934,"amount":9345.771694,"timestamp":1766413102251},"postHourTrading":{"tag":"盘后","latestPrice":2.49,"preClose":2.46,"latestTime":"19:12 EST","volume":3144,"amount":7704.716,"timestamp":1766448725935},"volumeRatio":0.299234,"impliedVol":4.4409,"impliedVolPercentile":1},"requestUrl":"/m/hq/s/PROK","defaultTab":"news","newsList":[{"id":"2591984893","title":"HC Wainwright Initiates Coverage on ProKidney With Buy Rating, $12 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2591984893","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591984893?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:38","pubTimestamp":1765888731,"startTime":"0","endTime":"0","summary":"ProKidney (PROK) has an average rating of overweight and mean price target of $6.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PROK","BK4139"],"gpt_icon":0},{"id":"2591981891","title":"ProKidney Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2591981891","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591981891?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:13","pubTimestamp":1765887180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PROK/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 16, 2025 07:13 ET (12:13 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PROK","BK4139"],"gpt_icon":0},{"id":"2591398509","title":"ProKidney Corp. : H.c. Wainwright Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2591398509","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591398509?lang=en_us&edition=fundamental","pubTime":"2025-12-16 19:09","pubTimestamp":1765883370,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nAZN4RFW8B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PROK","BK4139"],"gpt_icon":0},{"id":"2583681026","title":"ProKidney Corp. Director Brian JG Pereira Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2583681026","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583681026?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:09","pubTimestamp":1763154590,"startTime":"0","endTime":"0","summary":"Brian JG Pereira, Director of ProKidney Corp., has reported a disposal of common shares of ProKidney Corp. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prokidney Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 14, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL1Wrsx1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"ProKidney Corp. Director Brian JG Pereira Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PROK","BK4139"],"gpt_icon":0},{"id":"2582383803","title":"ProKidney Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $217.000K Beat $44.250K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582383803","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582383803?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:36","pubTimestamp":1762810564,"startTime":"0","endTime":"0","summary":"ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 13.04 percent. This is a 14.29 percent increase over losses of $(0.14) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48767698/prokidney-q3-eps-0-12-beats-0-14-estimate-sales-217-000k-beat-44-250k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ProKidney Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $217.000K Beat $44.250K Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":[".IXIC","TQQQ","TSYW.SI","PROK","BK4139","USAW.SI","QID","QLD","PSQ","NQmain","USJW.SI","SQQQ","NVIW.SI","MNQmain"],"gpt_icon":0},{"id":"2582030800","title":"ProKidney reports Q3 2025 results and updates on Phase 3 CKD therapy trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2582030800","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582030800?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:16","pubTimestamp":1762809379,"startTime":"0","endTime":"0","summary":"ProKidney Corp. reported cash, cash equivalents, and marketable securities totaling $271.7 million as of September 30, 2025, compared to $358.3 million at the end of 2024. The company expects these funds to support operations into mid-2027. More than half of the patients required for the Phase 3 PROACT 1 study for rilparencel have been enrolled, with topline results expected in the second quarter of 2027. The FDA confirmed that estimated glomerular filtration rate  slope can serve as the primary endpoint for a Biologics License Application submission for rilparencel under the accelerated approval pathway. Full Phase 2 results for rilparencel were recently presented, showing statistically significant stabilization of kidney function.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interprete","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL1NBkHm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PROK","BK4139"],"gpt_icon":0},{"id":"2582385110","title":"ProKidney: Q3 Net Loss per Share Attributable to Class a Stock $0.12","url":"https://stock-news.laohu8.com/highlight/detail?id=2582385110","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582385110?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:15","pubTimestamp":1762809302,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nPLXAFC7F2:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PROK","BK4139"],"gpt_icon":0},{"id":"2582800043","title":"Press Release: ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2582800043","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582800043?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:15","pubTimestamp":1762809300,"startTime":"0","endTime":"0","summary":"-- Full results from the Phase 2 REGEN-007 study of rilparencel were. recently presented as a late-breaking clinical trial at the American. -- More than half of the patients required for the Phase 3 REGEN-006 (PROACT. 1) accelerated approval analysis using estimated glomerular filtration. rate  slope have been enrolled; topline results anticipated in Q2. -- Ended the third quarter with $272 million in cash and cash equivalents. Phase 2 REGEN-007 Full Results Recently Presented at ASN Kidney Week 2025. On November 6, 2025, ProKidney presented full results from the Phase 2 REGEN-007 study evaluating rilparencel in patients with advanced CKD and diabetes. The data, featured in a late-breaking clinical trials presentation, further demonstrate the potential of rilparencel to preserve kidney function in patients with advanced CKD and diabetes who are at high risk of kidney failure. Highlights include:. in a 4.6 mL/min/1.73m2 improvement in the annual decline in eGFR slope;this 78% improvemen","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SOC","BK4213","PROK"],"gpt_icon":0},{"id":"2581002847","title":"Prokidney Corp  expected to post a loss of 13 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581002847","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581002847?lang=en_us&edition=fundamental","pubTime":"2025-11-07 19:53","pubTimestamp":1762516387,"startTime":"0","endTime":"0","summary":"Prokidney Corp  expected to post a loss of13cents a share - Earnings Preview Prokidney Corp PROK.OQ PROK.O is expected to  show no change in quarterly revenue when it reports  results on November 10 (","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ1BK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PROK"],"gpt_icon":0},{"id":"2581090619","title":"ProKidney Announces Phase 3 Trial Progress for Rilparencel in Advanced CKD and Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2581090619","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581090619?lang=en_us&edition=fundamental","pubTime":"2025-11-07 00:00","pubTimestamp":1762444818,"startTime":"0","endTime":"0","summary":"ProKidney Corp. has announced updated results from the Phase 2 REGEN-007 trial and provided an update on the ongoing Phase 3 PROACT 1 registrational program for rilparencel, its investigational autologous cell therapy for patients with advanced chronic kidney disease  and type 2 diabetes. Full results from the Phase 2 trial were presented at the American Society of Nephrology Kidney Week 2025. In the study, bilateral kidney injection with rilparencel demonstrated a statistically significant and clinically meaningful slowing of CKD progression, with a 4.6 mL/min/1.73m (78%) improvement in the annual decline of estimated glomerular filtration rate  slope in one patient group. No rilparencel-related serious adverse events were observed. The Phase 3 PROACT 1 trial is ongoing, with more than half of the approximately 360 patients required for the accelerated approval analysis already enrolled as of August 2025. The U.S. Food and Drug Administration  has confirmed that eGFR slope is an accep","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL317Sf7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2210150020.SGD","LU2095319765.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4588","PROK","NDAQ","LU2210149790.SGD","BK4585","BK4112","BK4139"],"gpt_icon":0},{"id":"2581905290","title":"ProKidney Presents Full Results From the Phase 2 Regen-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581905290","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581905290?lang=en_us&edition=fundamental","pubTime":"2025-11-07 00:00","pubTimestamp":1762444800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA5FSZL7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PROK"],"gpt_icon":0},{"id":"2579977409","title":"ProKidney Corp. to Join Guggenheim Healthcare Innovation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2579977409","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579977409?lang=en_us&edition=fundamental","pubTime":"2025-10-29 19:30","pubTimestamp":1761737416,"startTime":"0","endTime":"0","summary":"ProKidney Corp. will participate in the Guggenheim Healthcare Innovation Conference in Boston on November 12, 2025, where senior management will take part in a fireside chat. The presentation will be available via live webcast on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prokidney Corp. published the original content used to generate this news brief via GlobeNewswire  on October 29, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDL7j3jkx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","PROK","BK4585","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU0314104364.USD","NDAQ","LU2210149790.SGD","IE00B3QW5Z07.USD","BK4588","BK4139","IE00B64PRP62.GBP","LU2095319765.USD"],"gpt_icon":0},{"id":"2576064399","title":"BRIEF-Prokidney Corp to sell Greensboro property for $19.1 million - SEC filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2576064399","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576064399?lang=en_us&edition=fundamental","pubTime":"2025-10-18 05:03","pubTimestamp":1760735039,"startTime":"0","endTime":"0","summary":"BRIEF-Prokidney Corp to sell Greensboro property for $19.1 million - SEC filingOct 17  - Prokidney Corp PROK.O:PROKIDNEY CORP - TO SELL GREENSBORO PROPERTY FOR $19.1 MILLION - SEC FILINGSource text: [ID:n0001193125-25-242565]Further company coverage: PROK.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nFWN3VY33B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PROK"],"gpt_icon":0},{"id":"2576106157","title":"ProKidney Corp - to Sell Greensboro Property for $19.1 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2576106157","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576106157?lang=en_us&edition=fundamental","pubTime":"2025-10-18 04:37","pubTimestamp":1760733467,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nFWN3VY33B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PROK","BK4139"],"gpt_icon":0},{"id":"2575403214","title":"Discovering Potential: IZEA Worldwide And 2 Other Top Penny Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2575403214","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575403214?lang=en_us&edition=fundamental","pubTime":"2025-10-13 19:05","pubTimestamp":1760353507,"startTime":"0","endTime":"0","summary":"As U.S.-China trade tensions resurface, major stock indexes have posted significant weekly losses, highlighting the volatility in today's market. Despite this uncertainty, penny stocks—often smaller or newer companies—remain a relevant investment area for those seeking growth opportunities at lower price points. In this article, we explore three penny stocks that combine solid financial foundations with potential for impressive returns.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prok/prokidney/news/discovering-potential-izea-worldwide-and-2-other-top-penny-s","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prok/prokidney/news/discovering-potential-izea-worldwide-and-2-other-top-penny-s","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","IZEA","SELF.AU","BK4021","CURI","CINT","BK4134","BABB","BK4113","BK4084","PROK","BK4180","PSHG","WDH","BK4217","BK4173","BK4539","LCUT","BK4551","UUU","BK4209","BK4108","ERAS","BK4077","DDL","SELF","BK4509","BK4157"],"gpt_icon":0},{"id":"2572041546","title":"SPAC King Chamath Palihapitiya Tells Retail Investors To Stay Away From His New SPAC","url":"https://stock-news.laohu8.com/highlight/detail?id=2572041546","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572041546?lang=en_us&edition=fundamental","pubTime":"2025-10-02 23:32","pubTimestamp":1759419120,"startTime":"0","endTime":"0","summary":"Chamath Palihapitiya is back with another SPAC. This time he's telling retail investors to stay away. Here's why.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/02/SPAC.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/02/SPAC.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/ipos/25/10/47997701/spac-king-chamath-palihapitiya-retail-investors-stay-away-new-spac","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/ipos/25/10/47997701/spac-king-chamath-palihapitiya-retail-investors-stay-away-new-spac","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4551","BK4561","PSQ","QID","NVIW.SI","BK4547","SQQQ","USJW.SI","BK4139","IE00BD6J9T35.USD","TSYW.SI","BK4562","BK4079","BK4588","NQmain","QLD","AEXA","BK4564","BK4168","BK4535",".IXIC","MNQmain","SPCE","BK4166","PROK","BK4211","BK4154","CLOV","BK4585","BK4549","TQQQ","LU0505663152.USD","USAW.SI","BK4187","ISBC"],"gpt_icon":1},{"id":"2567903851","title":"ProKidney Leads Our Trio Of Promising Penny Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2567903851","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567903851?lang=en_us&edition=fundamental","pubTime":"2025-09-12 19:04","pubTimestamp":1757675098,"startTime":"0","endTime":"0","summary":"As the U.S. stock market reaches record highs, bolstered by inflation data that fuels hopes for interest rate cuts, investors are keenly exploring diverse opportunities. Penny stocks, often associated with smaller or newer companies, continue to present intriguing possibilities despite their seemingly outdated label. These stocks can offer significant growth potential when backed by strong financials and solid fundamentals, making them a noteworthy consideration for those looking to uncover...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prok/prokidney/news/prokidney-leads-our-trio-of-promising-penny-stocks","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prok/prokidney/news/prokidney-leads-our-trio-of-promising-penny-stocks","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7090","PBYI","BK4509","DDL","PROK","TUYA","WDH","BK4023","BK4113","BK4150","BK4526","TTI.AU","BK4505","BK4179","BK4021","BK4209","BABB","MAPS","TTI","PSHG","BK4139","BK4551","BK4539","TBTC","BK4173","BK4180","LCUT"],"gpt_icon":0},{"id":"2562669743","title":"ProKidney Corp. to Participate in Citi Biopharma Back to School and Morgan Stanley Global Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2562669743","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562669743?lang=en_us&edition=fundamental","pubTime":"2025-08-27 19:35","pubTimestamp":1756294508,"startTime":"0","endTime":"0","summary":"ProKidney Corp. , a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, announced that its senior management team will participate in the Citi Biopharma Back to School Conference in Boston on Wednesday, September 3, 2025. The event will include a fireside chat scheduled for 10:30 am ET.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prokidney Corp. published the original content used to generate this news brief via GlobeNewswire  on August 27, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nNDL5k0VgM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","BK4504","LU0320765646.SGD","LU0098860793.USD","LU1267930227.SGD","LU2462157665.USD","LU2210149790.SGD","LU2125154935.USD","LU0130102774.USD","LU2456880835.USD","LU1668664300.SGD","BK4139","IE00BGHQF748.EUR","NDAQ","LU0128525689.USD","BK4588","IE00BSNM7G36.USD","PROK","LU1791807156.HKD","BK4585","IE00B3QW5Z07.USD","LU2417539215.USD","LU2125154778.USD","BK4559","LU1162221912.USD","LU0052756011.USD","LU0170899867.USD","IE00BKPKM429.USD","LU0648001328.SGD","IE00B64PRP62.GBP","LU2095319765.USD","LU0162691827.USD","BK4207","LU2236285917.USD","LU2360032135.SGD","BK4534","LU0310800965.SGD","LU0980610538.SGD","LU0130517989.USD","LU1366192091.USD","LU0106831901.USD","BK4566","LU2210150020.SGD","LU1244550577.SGD","LU1244550221.USD","LU1244550494.USD","LU0072461881.USD","LU1201861249.SGD","BK4112"],"gpt_icon":0},{"id":"2559629122","title":"ProKidney Q2 EPS $(0.13) Beats $(0.15) Estimate, Sales $221.000K","url":"https://stock-news.laohu8.com/highlight/detail?id=2559629122","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559629122?lang=en_us&edition=fundamental","pubTime":"2025-08-13 04:05","pubTimestamp":1755029144,"startTime":"0","endTime":"0","summary":"ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 18.75 percent increase over losses of $(0.16) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47073740/prokidney-q2-eps-0-13-beats-0-15-estimate-sales-221-000k","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ProKidney Q2 EPS $(0.13) Beats $(0.15) Estimate, Sales $221.000K","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PROK"],"gpt_icon":0},{"id":"2559629118","title":"ProKidney Announces Positive Phase 2 REGEN-007 Results and FDA Alignment for Accelerated Approval Pathway of Rilparencel","url":"https://stock-news.laohu8.com/highlight/detail?id=2559629118","media":"Reuters","labels":["productRelease","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559629118?lang=en_us&edition=fundamental","pubTime":"2025-08-13 04:03","pubTimestamp":1755028993,"startTime":"0","endTime":"0","summary":"ProKidney Corp., a company specializing in cell therapeutics for chronic kidney disease, has announced the positive topline results from its Phase 2 REGEN-007 study. The study demonstrated a 78% improvement in the eGFR slope in Group 1 after treatment with rilparencel. Full results from the REGEN-007 study are set to be submitted as a late-breaking clinical trial at the American Society of Nephrology 2025 Kidney Week. Additionally, the FDA has confirmed the use of the eGFR slope as a surrogate endpoint for accelerated approval of rilparencel in patients with type 2 diabetes and advanced chronic kidney disease. The ongoing Phase 3 PROACT 1 study will serve as both the accelerated approval and confirmatory study, with topline data expected in the second quarter of 2027. ProKidney continues to enroll patients for this study and aims to bring a novel treatment option to address the unmet clinical needs in this patient population.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDL9V8LMN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2210149790.SGD","LU2210150020.SGD","BK4588","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","BK4585","BK4139","PROK","IE00B64PRP62.GBP","NDAQ","BK4112","IE00BKPKM429.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.prokidney.com","stockEarnings":[{"period":"1week","weight":0.1827},{"period":"1month","weight":0.1233},{"period":"3month","weight":-0.1022},{"period":"6month","weight":2.1907},{"period":"1year","weight":0.6291},{"period":"ytd","weight":0.4556}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":0.0391},{"period":"3month","weight":0.0326},{"period":"6month","weight":0.128},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1685}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":0.056658},{"month":2,"riseRate":0.75,"avgChangeRate":0.02865},{"month":3,"riseRate":0.5,"avgChangeRate":-0.077784},{"month":4,"riseRate":0.5,"avgChangeRate":0.025444},{"month":5,"riseRate":0.75,"avgChangeRate":0.19736},{"month":6,"riseRate":0.25,"avgChangeRate":-0.136783},{"month":7,"riseRate":0.4,"avgChangeRate":0.747675},{"month":8,"riseRate":0.2,"avgChangeRate":-0.09753},{"month":9,"riseRate":0.4,"avgChangeRate":-0.139421},{"month":10,"riseRate":0.6,"avgChangeRate":-0.082174},{"month":11,"riseRate":0.4,"avgChangeRate":-0.019735},{"month":12,"riseRate":0.6,"avgChangeRate":-0.046262}],"exchange":"NASDAQ","name":"ProKidney Corp.","nameEN":"ProKidney Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ProKidney Corp.(PROK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ProKidney Corp.(PROK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ProKidney Corp.,PROK,ProKidney Corp.股票,ProKidney Corp.股票老虎,ProKidney Corp.股票老虎国际,ProKidney Corp.行情,ProKidney Corp.股票行情,ProKidney Corp.股价,ProKidney Corp.股市,ProKidney Corp.股票价格,ProKidney Corp.股票交易,ProKidney Corp.股票购买,ProKidney Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ProKidney Corp.(PROK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ProKidney Corp.(PROK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction